Concourse Financial Group Securities, Inc. In8 Bio, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding INAB
# of Institutions
27Shares Held
7.99MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD2.13MShares$680,9590.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$455,6470.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT1.12MShares$357,8450.0% of portfolio
-
Sigma Planning Corp Ann Arbor, MI851KShares$272,4090.01% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL641KShares$205,1220.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $7.84M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...